Using dapagliflozin to reduce symptoms in transthyretin cardiac amyloidosis: An n-of-1 trial series pilot study. Hakansson E, Anan I, Brunstrom M, Hellstrom-Angerud K, et al. PLoS One 2026;21:e0346065.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hakansson E, Anan I, Brunstrom M, Hellstrom-Angerud K, et al. Using dapagliflozin to reduce symptoms in transthyretin cardiac amyloidosis: An n-of-1 trial series pilot study. PLoS One 2026;21:e0346065.
PMID: 42842573